Shionogi & Co., Ltd.
Completion of Full Acquisition of U.S. IntraBio, Inc.
Announced completion of acquisition of IntraBio. Through expansion of the AQNEURSA neurological treatment portfolio and strengthening global capabilities in rare diseases, the company will expand its clinical development and commercial base in rare disease areas.
Key Figures
- AQNEURSA approval status: Approved by U.S. FDA / European EMA (adult & pediatric / with weight requirements), additional approval for A-T depends on FDA developments
- Acquisition completion date: Announced October 5, 2026; disclosure of acquisition completion date and consolidated impact was incorporated into the revised forecast on October 29, 2026
- Related disease programs: Initiation and continuation of Phase 3 trial for CACNA1A-related disorders
AI要約
Overview of the News
Shionogi & Co., Ltd. announced the completion of the full acquisition of U.S.-based IntraBio, Inc. This expands the AQNEURSA portfolio for NPC neurological symptoms and A-T ataxia treatments and strengthens the company’s global efforts in rare diseases. AQNEURSA is approved by the U.S. FDA and the European EMA; FDA approval for A-T patients was granted in September 2026.
Future Development and Outlook
Shionogi will continue and expand programs led by IntraBio, including the Phase 3 trial for CACNA1A-related disorders, and will assess clinical development opportunities in rare disease areas. Ongoing clinical development programs for Pompe disease, fragile X syndrome, and Jordan's syndrome will also continue to be advanced.
Shionogi & Co., Ltd.
Company overview · Stock price · Financial data · All IR